A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Latest Information Update: 04 Sep 2026
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Delayed graft function
- Focus Registrational; Therapeutic Use
- Sponsors Apellis Pharmaceuticals
Most Recent Events
- 02 Sep 2026 Status changed from suspended to withdrawn prior to enrolment.
- 18 Jun 2026 Planned End Date changed from 1 Aug 2028 to 1 Jul 2030.
- 18 Jun 2026 Planned primary completion date changed from 1 Aug 2027 to 1 Jun 2029.